(Q37318762)

19 August 2017

1 reference

title

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy (English)

1 reference

B-cell chronic lymphocytic leukemia

19 August 2017

0 references

1 reference

1 reference

S Faderl

1

1 reference

19 August 2017

A Ferrajoli

series ordinal

2

1 reference

19 August 2017

O Frankfurt

series ordinal

3

1 reference

19 August 2017

A Pettitt

series ordinal

4

1 reference

19 August 2017

6 November 2008

1 reference

19 August 2017

1 reference

19 August 2017

23

1 reference

19 August 2017

457-466

1 reference

19 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.322

19 August 2017

0 references

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

The pathogenesis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Monoclonal antibodies for B-cell lymphomas: rituximab and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Structure and functions of CD23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Thymocyte apoptosis induced by p53-dependent and independent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Overview of cancer epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

The ubiquitin-proteasome pathway and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

miR-15 and miR-16 induce apoptosis by targeting BCL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Cellular immune therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Vaccine- and immune-based therapy in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Differential STAT3, STAT5, and NF-kappaB activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

The p53 pathway: positive and negative feedback loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

High dose methyl prednisolone in refractory chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

https://api.crossref.org/works/10.1038%2FLEU.2008.322

1 reference

7 January 2021

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.322

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.322

1 reference

Dimensions Publication ID

19 August 2017

0 references

1 reference